Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo Inc. (MYO) is a leader in developing wearable medical robotics that restore mobility for individuals with neuromuscular disorders. This page serves as the definitive source for official company announcements, providing stakeholders with timely updates on innovations shaping the orthotics industry.
Access curated press releases covering FDA milestones, product launches, and financial performance reports. Investors will find earnings disclosures and partnership announcements, while healthcare professionals can track clinical trial outcomes and insurance coverage expansions.
Our repository includes updates on Myomo’s myoelectric brace development, research collaborations with medical institutions, and regulatory progress across global markets. All content is sourced directly from company filings and verified channels to ensure accuracy.
Bookmark this page to monitor how MYO’s neuro-robotic solutions are advancing patient care while creating long-term value in the medical technology sector. Check regularly for developments impacting both clinical and investment communities.
Myomo (NYSE: MYO) reported Q3 2025 revenue of $10.1M, up 10% year-over-year, driven by 186 MyoPro units and record authorizations/orders (229) in the quarter. Year-to-date revenue was $29.6M, up 44% versus prior year. Gross margin declined to 63.8% (Q3) from 75.4% a year earlier, primarily due to lower ASP, higher material and labor costs, and overhead absorption. Q3 net loss was $3.7M (loss of $0.09/share); adjusted EBITDA was $(2.7)M. The company entered a $17.5M debt facility (Nov 4, 2025) with $12.5M funded and reported pro forma cash of $20.1M as of Sept 30, 2025. Myomo reiterated full‑year 2025 revenue guidance of $40M–$42M.
Myomo (NYSE American: MYO) will report third quarter 2025 financial results on Monday, November 10, 2025. Management will host a conference call at 4:30 p.m. Eastern to review results, provide a business update, and answer questions.
Participants may pre-register to receive a dial-in number and PIN or join by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A live webcast and replay will be available at https://ir.myomo.com/. A dial-in replay is available until November 24, 2025 at 855-669-9658 (U.S. toll free) or 412-317-0088 (International) using access code 4112515.
Myomo (NYSE American: MYO), a wearable medical robotics company specializing in solutions for neurological disorders and upper-limb paralysis, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The conference will take place from September 8-10, 2025 at the Lotte New York Palace Hotel. Company executives Paul Gudonis (CEO) and David Henry (CFO) will deliver an on-demand presentation and be available for one-on-one meetings with registered investors.
Myomo (NYSE American: MYO) reported Q2 2025 financial results with revenue of $9.7 million, up 28% year-over-year. The company delivered 178 MyoPro units, a 13% increase, with 56% of revenue from Medicare Part B patients. Average selling price rose 14% to $54,200.
Despite revenue growth, the company faced challenges with lead quality and pipeline conversion, leading to updated 2025 revenue guidance of $40-42 million, down from previous $50-53 million. The company implemented cost-reduction measures, including an 8% workforce reduction, expected to save $2 million over 12 months.
Q2 operating loss widened to $4.6 million from $1.1 million year-over-year, with cash position at $15.5 million as of June 30, 2025. The company expects Q3 2025 revenue between $9.5-10.0 million.
Myomo (NYSE American: MYO), a wearable medical robotics company specializing in solutions for neurological disorders and upper-limb paralysis, has scheduled its Q2 2025 financial results release for August 11, 2025.
The company will host a conference call at 4:30 p.m. Eastern time to discuss results and provide business updates. Participants can pre-register online to receive dial-in credentials, or join directly using U.S. (844-707-6932) or International (412-317-9250) numbers. A webcast replay will be available on the investor relations website, and a dial-in replay will be accessible until August 25, 2025.
- Gross margin improved to 67.2%, up 600 basis points - Medicare Part B patients represented 59% of Q1 revenue - Record 700 new candidates added to pipeline, up 42% - Average selling price increased to $54,000, up 31%
Despite positive revenue growth, the company faced challenges with Medicare Advantage plans and social media algorithm changes affecting lead generation. Operating loss narrowed to $3.5 million from $3.9 million year-over-year. The company maintains its full-year 2025 revenue guidance of $50-53 million, projecting 54-63% growth compared to 2024.
Myomo (NYSE American: MYO), a wearable medical robotics company, announces its first-ever Investor & Analyst Day scheduled for June 18, 2025. The event will be held at the company's new corporate headquarters in Burlington, Massachusetts, from 10:00 a.m. to 3:00 p.m. ET. The event will feature presentations from senior management, product demonstrations of the MyoPro® powered arm and hand brace, Q&A sessions, and facility tours. Both in-person and virtual attendance options are available, with the event being webcast live and available for replay. The company will showcase its latest innovations, strategic plans, and growth initiatives in wearable medical robotics for individuals with neuromuscular disorders.
Myomo, a wearable medical robotics company focused on helping patients with neurological disorders and upper-limb paralysis, has scheduled its Q1 2025 financial results announcement for May 7, 2025.
The company will host a conference call at 4:30 p.m. ET, featuring prepared remarks from Paul R. Gudonis, chairman and CEO, and David Henry, CFO. Participants can pre-register for the call through a provided link to receive immediate access via a unique PIN and passcode.
Alternative dial-in options include:
- U.S. callers: 844-707-6932
- International callers: 412-317-9250
A webcast will be available on Myomo's Investor Relations page, with replay access until May 21, 2025. The replay can be accessed via:
- U.S. toll-free: 877-344-7529
- Canada toll-free: 855-669-9658
- International: 412-317-0088
- Access code: 1943669
Myomo has launched the MyoPro 2x, an advanced wearable medical robotics device designed to improve arm and hand function for people with upper-limb paralysis and neuromuscular conditions. The new model features significant improvements in donning, fit, and function, building on experience from over 3,000 previous patients.
Key enhancements include:
- Streamlined and intuitive donning process for consistent fit
- Integration of common customizations into standard design
- Reduced clinician fitting time
- Updated training documentation and instruction guides
Supporting the launch, Myomo has implemented a certification process for Orthotic & Prosthetic providers to become MyoPro Centers of Excellence. This enables certified practices to independently build patient pipelines and dispense the MyoPro 2x. The development process incorporated feedback from users and clinicians, along with Myomo's product performance data.
FAQ
What is the current stock price of Myomo (MYO)?
What is the market cap of Myomo (MYO)?
